Spruce Biosciences, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 46.82 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 134.56M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Details
| Name | Spruce Biosciences, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 22 |
| Founded | 2014 |
| Ceo | Javier Szwarcberg |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US85209E2081 |
| Cusip | 85209E208 |
| Cik | 0001683553 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Javier Szwarcberg M.D., M.P.H. | Chief Executive Officer and Director |
| Michael G. Grey | Executive Chairman |
| Samir M. Gharib CPA, M.B.A. | President and Chief Financial Officer |
| Eric Jordan M.B.A. | Vice President of Marketing |
| Bruno Gagnon BPHARM, M.Sc. | Senior Vice President of Clinical Development Operations |
| Dr. Daven Mody M.B.A., Pharm.D. | Senior Vice President of Regulatory and Quality |
| Corwin Dale Hooks M.B.A. | Chief Commercial Officer |
| Dr. Adrian Quartel FFPM, M.D. | Chief Medical Officer |
| Saba Sile M.D. | Senior Vice President of Clinical Development |
| Tina Gullotta CPA | Vice President of Finance and Corporate Controller |
Contact
| Address | 611 Gateway Boulevard, Suite 740, South San Francisco, California 94080, United States |
| Phone | 415 343 5986 |
| Website | https://sprucebio.com |